Janet Sim

Statistics

Publications

Citations

325

H-Index

Active since

2018

Affiliations

Collaborative Drug Discovery (United States)(Current)

Janet Sim is an author at Collaborative Drug Discovery (United States) specializing in cancer immunology, immunology, and immune checkpoint regulation.

ORCID

Publications per year

2018–2021

Publications

ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile

Steven E. Kauder, Tracy C. Kuo, Ons Harrabi et al. · PLoS ONE · 2018 · 171 citations · Full text

Medicine, Immunology, Oncology +17

Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity

Tracy C. Kuo, Amy Chen, Ons Harrabi et al. · Journal of Hematology & Oncology · 2020 · 74 citations · Full text

Life Sciences, Immunology, Oncology +17

Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRPα

Janet Sim, Jonathan T. Sockolosky, Emma Sangalang et al. · mAbs · 2019 · 50 citations · Full text

Life Sciences, Immunology, Oncology +15

Assessing and mitigating the interference of <scp>ALX148</scp>, a novel <scp>CD47</scp> blocking agent, in pretransfusion compatibility testing

Tae Yeul Kim, Mi Sook Yoon, Hein Hustinx et al. · Transfusion · 2020 · 17 citations

Medicine, Hematology, Immunology +15

Abstract 1721: TAC-001, a toll-like receptor 9 (TLR9) agonist antibody conjugate targeting B cells, promotes anti-tumor immunity and favorable safety profile following systemic administration in preclinical models

Tracy C. Kuo, Ons Harrabi, Amy Chen et al. · Cancer Research · 2021 · 13 citations

Life Sciences, Immunology, Oncology +17

1–5 of 5